Anticancer properties of zoledronic acid

Jonathan Green, Allan Lipton

Research output: Contribution to journalReview articlepeer-review

27 Scopus citations


Zoledronic acid effectively reduces/delays skeletal-related events in patients with metastatic disease or skeletal-related cancers. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. Zoledronic acid ± anticancer therapies in animal models inhibits soft-tissue tumor growth, decreases tumor cell proliferation, increases apoptosis, inhibits angiogenesis, alters tumor-associated macrophage function, and enhances immune surveillance. Data from in vitro and pilot studies suggest that zoledronic acid inhibits tumor cell dissemination in bone marrow, and early clinical data show that it may improve disease-related outcomes. Ongoing studies will further elucidate the role of zoledronic acid in cancer patients.

Original languageEnglish (US)
Pages (from-to)944-957
Number of pages14
JournalCancer Investigation
Issue number9
StatePublished - Oct 2010

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Anticancer properties of zoledronic acid'. Together they form a unique fingerprint.

Cite this